These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 24297267)

  • 1. The polymicrobial Actinomyces naeslundii and Pseudomonas aeruginosa sepsis in a patient with ulcerative colitis 2 months after colonoscopy.
    Topić MB; Desnica B; Vicković N; Skuhala T; Bayer K; Bukovski S
    Wien Klin Wochenschr; 2014 Feb; 126(3-4):130-2. PubMed ID: 24297267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors, clinical features, and outcome of Pseudomonas aeruginosa bacteremia in patients with hematologic malignancies: a case-control study.
    Vuotto F; Berthon C; Lemaitre N; Duhamel A; Balkaran S; Le Ray E; Micol JB; Faure K; Alfandari S
    Am J Infect Control; 2013 Jun; 41(6):527-30. PubMed ID: 23219670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [On the way to optimal Pseudomonas aeruginosa bacteriemia therapy].
    Cobo Reinoso J; Moreno Guillén S
    Rev Clin Esp; 2004 Sep; 204(9):445-7. PubMed ID: 15388016
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical impact of imipenem-resistant Pseudomonas aeruginosa bloodstream infections.
    Suárez C; Peña C; Tubau F; Gavaldà L; Manzur A; Dominguez MA; Pujol M; Gudiol F; Ariza J
    J Infect; 2009 Apr; 58(4):285-90. PubMed ID: 19297028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pseudomonas aeruginosa bacteremia secondary to fingerstick glucose monitoring.
    Jen SP; Sharma R; Ravishankar J
    J Infect; 2010 May; 60(5):382-5. PubMed ID: 20036280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does the piperacillin minimum inhibitory concentration for Pseudomonas aeruginosa influence clinical outcomes of children with pseudomonal bacteremia?
    Tamma PD; Turnbull AE; Milstone AM; Hsu AJ; Carroll KC; Cosgrove SE
    Clin Infect Dis; 2012 Sep; 55(6):799-806. PubMed ID: 22696019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bacterial meningitis and Pseudomonas aeruginosa: apropos of a case].
    Batlle Almodóvar Mdel C; Dickinson F; Pérez Monrás M; Tamargo Martínez I; Similis A
    Rev Cubana Med Trop; 2005; 57(3):230-2. PubMed ID: 17969281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Curious Case of Actinomyces Naeslundii Bacteremia in a Patient with Metastatic Pancreatic Cancer.
    De Keyser R; Ram A; Dasanu CA
    Conn Med; 2016 Sep; 80(7):417-418. PubMed ID: 29782130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ecthyma gangrenosum: sign of Pseudomonas aeruginosa bacteremia.
    Demircioğlu F; Oren H
    Pediatr Hematol Oncol; 2008 Jun; 25(4):369-70. PubMed ID: 18484484
    [No Abstract]   [Full Text] [Related]  

  • 10. Is central venous catheter tip colonization with Pseudomonas aeruginosa a predictor for subsequent bacteremia?
    Apisarnthanarak A; Apisarnthanarak P; Warren DK; Fraser VJ
    Clin Infect Dis; 2012 Feb; 54(4):581-3. PubMed ID: 22156851
    [No Abstract]   [Full Text] [Related]  

  • 11. Actinomyces neuii and neonatal sepsis.
    Mann C; Dertinger S; Hartmann G; Schurz R; Simma B
    Infection; 2002 Jun; 30(3):178-80. PubMed ID: 12120948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Actinomyces odontolyticus bacteremia.
    Cone LA; Leung MM; Hirschberg J
    Emerg Infect Dis; 2003 Dec; 9(12):1629-32. PubMed ID: 14720410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a combination antibiogram for Pseudomonas aeruginosa bacteremia in an oncology population.
    Smith ZR; Tajchman SK; Dee BM; Bruno JJ; Qiao W; Tverdek FP
    J Oncol Pharm Pract; 2016 Jun; 22(3):409-15. PubMed ID: 25956419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orbital cellulitis and endophthalmitis in pseudomonas septicemia.
    Luemsamran P; Pornpanich K; Vangveeravong S; Mekanandha P
    Orbit; 2008; 27(6):455-7. PubMed ID: 19085303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for the failure of treatment of
    Yoshida S; Suzuki K; Suzuki A; Okada H; Niwa T; Kobayashi R; Murakami N; Ogura S; Itoh Y
    Pharmazie; 2017 Jul; 72(7):428-432. PubMed ID: 29441942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of borderline cefepime MIC on the outcome of cefepime-susceptible Pseudomonas aeruginosa bacteremia treated with a maximal cefepime dose: a hospital-based retrospective study.
    Su TY; Ye JJ; Yang CC; Huang CT; Chia JH; Lee MH
    Ann Clin Microbiol Antimicrob; 2017 Jul; 16(1):52. PubMed ID: 28738848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination antibiotic therapy for Pseudomonas aeruginosa bacteraemia.
    Paul M; Leibovici L
    Lancet Infect Dis; 2005 Apr; 5(4):192-3; discussion 193-4. PubMed ID: 15792730
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteraemia: a stratified analysis according to sites of infection.
    Joo EJ; Kang CI; Ha YE; Park SY; Kang SJ; Wi YM; Lee NY; Chung DR; Peck KR; Song JH
    Infection; 2011 Aug; 39(4):309-18. PubMed ID: 21594653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pseudomonas aeruginosa bacteremia].
    Inamatsu T
    Nihon Rinsho; 1991 Oct; 49(10):2331-5. PubMed ID: 1749089
    [No Abstract]   [Full Text] [Related]  

  • 20. Time-to-positivity of blood culture: An independent prognostic factor of monomicrobial Pseudomonas aeruginosa bacteremia.
    Tang PC; Lee CC; Li CW; Li MC; Ko WC; Lee NY
    J Microbiol Immunol Infect; 2017 Aug; 50(4):486-493. PubMed ID: 26455486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.